Email updates

Keep up to date with the latest news and content from Journal of Cardiovascular MR and BioMed Central.

Open Access Highly Accessed Review

Minimizing Risk of Nephrogenic systemic fibrosis in Cardiovascular Magnetic Resonance

Theresa Reiter1*, Oliver Ritter1, Martin R Prince2, Peter Nordbeck1, Christoph Wanner1, Eike Nagel3 and Wolfgang Rudolf Bauer1

Author Affiliations

1 Department of Internal Medicine I, Divisions of Cardiology and Nephrology, University Hospital Wuerzburg, Wuerzburg, Germany

2 Department of Radiology, Cornell & Columbia Universities, New York, USA

3 Division of Imaging Sciences, King’s College London, London, UK

For all author emails, please log on.

Journal of Cardiovascular Magnetic Resonance 2012, 14:31  doi:10.1186/1532-429X-14-31

Published: 20 May 2012

Abstract

Nephrogenic Systemic Fibrosis is a rare condition appearing only in patients with severe renal impairment or failure and presents with dermal lesions and involvement of internal organs. Although many cases are mild, an estimated 5 % have a progressive debilitating course. To date, there is no known effective treatment thus stressing the necessity of ample prevention measures. An association with the use of Gadolinium based contrast agents (GBCA) makes Nephrogenic Systemic Fibrosis a potential side effect of contrast enhanced magnetic resonance imaging and offers the opportunity for prevention by limiting use of gadolinium based contrast agents in renal failure patients. In itself toxic, Gadolinium is embedded into chelates that allow its safe use as a contrast agent. One NSF theory is that Gadolinium chelates distribute into the extracellular fluid compartment and set Gadolinium ions free, depending on multiple factors among which the duration of chelates exposure is directly related to the renal function. Major medical societies both in Europe and in North America have developed guidelines for the usage of GBCA. Since the establishment of these guidelines and the increased general awareness of this condition, the occurrence of NSF has been nearly eliminated. Giving an overview over the current knowledge of NSF pathobiochemistry, pathogenesis and treatment options this review focuses on the guidelines of the European Medicines Agency, the European Society of Urogenital Radiology, the FDA and the American College of Radiology from 2008 up to 2011 and the transfer of this knowledge into every day practice.